Want to join the conversation?
$GILD 2Q15 Call: Non-GAAP R&D expenses were $702MM, up 30% YoverY due to continued progression and expansion of clinical studies, particularly Phase 3 studies in liver disease and oncology areas. Non-GAAP SG&A expenses were up 34% YoverY to $761MM. Ended 2Q15 with $14.7Bil in cash and investments, and generated cash flow from operations of $5.7Bil.
$AAL is getting stronger into Dec. after a strong Nov..!! I’m feeling confident about their 4Q revenue forecast for a margin rise.
$KO’s CEO Muhtar Kent to step down next year. COO James Quincey will take the helm in what is already a smooth sailing scenario. And as always, shares reflect by growing 2% after the market opened.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.